RANCHO CORDOVA, Calif., June 23, 2026
SK pharmteco has introduced SKyvec™, a next-generation multimodal viral vector platform designed to accelerate gene therapy development from early-stage research through commercial manufacturing. The proprietary platform combines advanced process development, scalable manufacturing technologies, and integrated analytical capabilities into a unified framework that supports Adeno-Associated Virus (AAV), Lentiviral (Lenti), and Adenoviral (Adeno) vector production. By integrating development and manufacturing across facilities in North America and Europe, SKyvec™ enables biotechnology and biopharmaceutical companies to streamline development timelines, improve manufacturing efficiency, and accelerate the delivery of innovative gene therapies to patients. The launch reflects the growing demand for scalable, regulatory-ready viral vector manufacturing solutions as the global gene therapy pipeline continues to expand and developers seek faster, more reliable pathways from laboratory research to clinical and commercial production.
Unified Viral Vector Platform Supports Every Stage of Development
The SKyvec™ platform provides a comprehensive viral vector development and manufacturing solution capable of supporting programs from early research, process optimization, clinical manufacturing, and commercial-scale production. The platform combines cell line development, plasmid manufacturing, process development, drug substance production, analytical testing, and regulatory support within a single integrated framework. Developers can select customized manufacturing workflows tailored to individual therapeutic programs while maintaining flexibility across multiple vector systems.
SKyvec™ AAV utilizes a HEK293-based suspension manufacturing process that delivers high-yield production with integrated analytics for research and clinical supply. SKyvec™ Lenti supports both ex vivo and in vivo gene therapy programs, offering scalable suspension processing from early development through commercialization. SKyvec™ Adeno provides optimized adherent and suspension manufacturing processes capable of supporting full commercial production. Together, these capabilities enable pharmaceutical and biotechnology companies to simplify technology transfer while reducing development complexity across multiple gene therapy applications.
High-Yield Manufacturing Improves Efficiency and Scalability
Advertisement
A key innovation of SKyvec™ is its ability to significantly improve manufacturing productivity while reducing production costs. SK pharmteco reports that the platform delivers five- to six-fold productivity gains in AAV manufacturing, alongside improved full-capsid ratios, addressing some of the industry’s most significant manufacturing bottlenecks. Supported by a dedicated Manufacturing Science and Technology (MSAT) team, the platform is engineered to minimize variability during process scale-up and technology transfer. Upstream development is currently performed at scales of up to 200 liters, with validated expansion pathways to 500-liter and 1,000-liter bioreactors, fully aligned with current Good Manufacturing Practice (cGMP) standards.
While suspension-based manufacturing offers maximum scalability for commercial production, developers also retain access to an adherent AAV platform, providing additional flexibility based on program-specific manufacturing requirements and therapeutic applications.
Global CDMO Capabilities Advance Gene Therapy Manufacturing
The launch of SKyvec™ further strengthens SK pharmteco’s position as a global contract development and manufacturing organization (CDMO) serving the rapidly growing cell and gene therapy sector. Available across the company’s manufacturing facilities in the United States and Europe, the platform supports multiple viral serotypes, novel genetic constructs, and diverse transgene applications while integrating cell banking, viral banking, analytical testing, quality systems, and global regulatory expertise. As gene therapy developers continue to expand clinical pipelines targeting rare diseases, oncology, inherited disorders, and regenerative medicine, scalable manufacturing remains one of the industry’s greatest challenges.
SKyvec™ addresses these needs by combining high-yield viral vector production, flexible process development, robust analytical capabilities, and global manufacturing infrastructure into a single solution capable of supporting programs from discovery through commercialization. By reducing manufacturing complexity, improving process consistency, and accelerating development timelines, SK pharmteco aims to help biopharmaceutical innovators bring transformative gene therapies to patients more efficiently while supporting the next generation of precision medicines worldwide.
Source: SK pharmteco press release
